Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer

被引:549
作者
van Meerbeeck, Jan P.
Kramer, Gijs W. P. M.
Van Schil, Paul E. Y.
Legrand, Catherine
Smit, Egbert F.
Schramel, Franz
Tjan-Heijnen, Vivianne C.
Biesma, Bonne
Debruyne, Channa
van Zandwijk, Nico
Splinter, Ted A. W.
Giaccone, Giuseppe
机构
[1] Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium
[2] Arnhem Radiotherapeut Inst, Dept Radiat Therapy, Arnhem, Netherlands
[3] Univ Hosp Antwerp, Dept Resp Med, Antwerp, Belgium
[4] Univ Hosp Antwerp, Dept Thorac Surg, Antwerp, Belgium
[5] European Org Res Treatment Canc, Ctr Data, Brussels, Belgium
[6] Vrije Univ Amsterdam, Dept Pulmonol, Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[8] St Antonius Hosp, Dept Pulmonol, Nieuwegein, Netherlands
[9] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[10] Jeroen Bosch Ziekenhuis, Dept Pulmonol, Shertogenbosch, Netherlands
[11] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[12] Erasmus MC, Dept Pulmonol, Rotterdam, Netherlands
[13] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2007年 / 99卷 / 06期
关键词
D O I
10.1093/jnci/djk093
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non-small-cell lung cancer (NSCLC). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy. Methods Selected patients with histologic or cytologic proven stage IIIA-N2 NSCLC were given three cycles of platinum-based induction chemotherapy. Responding patients were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan-Meier analyses from time of randomization. Results Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [Cl] = 57% to 65%) among the 579 eligible patients. A total of 167 patients were allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one patient died of radiation pneumonitis. Median and 5-year overall survival for patients randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% Cl = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups. Conclusion In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 41 条
[1]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[2]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[3]   Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications [J].
Andre, F ;
Grunenwald, D ;
Pignon, JP ;
Dujon, A ;
Pujol, JL ;
Brichon, PY ;
Brouchet, L ;
Quoix, E ;
Westeel, V ;
Le Chevalier, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2981-2989
[4]  
[Anonymous], 1993, 50 ICRU
[5]  
[Anonymous], 2005, J Clin Oncol
[6]   Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].
Betticher, DC ;
Schmitz, SFH ;
Tötsch, M ;
Hansen, E ;
Joss, C ;
von Briel, C ;
Schmid, RA ;
Pless, M ;
Habicht, J ;
Roth, AD ;
Spiliopoulos, A ;
Stahel, R ;
Weder, W ;
Stupp, R ;
Egli, F ;
Furrer, M ;
Honegger, H ;
Wernli, M ;
Cerny, T ;
Ris, HB .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1752-1759
[7]   Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984) [J].
Biesma, B. ;
Manegold, C. ;
Smit, H. J. M. ;
Willems, L. ;
Legrand, C. ;
Passioukov, A. ;
van Meerbeeck, J. P. ;
Giaccone, G. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) :1399-1406
[8]   Surgeon volume and operative mortality in the United States [J].
Birkmeyer, JD ;
Stukel, TA ;
Siewers, AE ;
Goodney, PP ;
Wennberg, DE ;
Lucas, FL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2117-2127
[9]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[10]   Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival [J].
Bueno, R ;
Richards, WG ;
Swanson, SJ ;
Jaklitsch, MT ;
Lukanich, JM ;
Mentzer, SJ ;
Sugarbaker, DJ .
ANNALS OF THORACIC SURGERY, 2000, 70 (06) :1826-1831